Advertisement

Topics

Selective monoamine oxidase type B MAOB inhibitors - Biotech, Pharma and Life Science Channel

03:33 EDT 24th June 2018 | BioPortfolio

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additionally, basic research suggests that MAO-B inhibitors may impart efficacy by inhibiting apoptosis (programmed cell death). There are two MAO-B inhibitors available today, selegiline and rasagiline.

Selegiline is an irreversible, relatively selective (its selectivity is lost at higher doses) MAO-B inhibitor. Selegiline possesses other pharmacological activities such as an effect on mitochondrial membrane potential activity, an antiapoptosis effect and reduction of oxidative stress which may play a role in its putative neuroprotective effect. When administered orally, selegiline has low bioavailability as a result of extensive hepatic first-pass metabolism. This metabolism produces high levels of amphetamine metabolites; l-methamphetamine and l-amphetamine account for more than three-fourths of the recovered metabolites from an oral dose of conventional selegiline. There is also an orally disintegrating tablet (ODT) of selegiline which has advantages including rapid onset of action, avoidance of presystemic metabolism to provide higher drug levels and decreased plasma concentrations of amphetamine metabolites.

Azilect or Rasagiline and its analogues are under investigation for Alzheimer's disease. They apparently enhance memory and learning. Rasagiline may also improve mood, motivation and age-related memory decline in the ageing but nominally well adult population.

 The novel cholinesterase-brain selective MAO-AB inhibitor, TV3326, a carbamte derivative of the irreversible MAO-B inhibitor anti-Parkinson drug, rasagiline is a brain selective MAO-A and B inhibitor, with little inhibition of liver and small intestine enzymes. Pharmacologically it has limited tyramine potentiation, very similar to moclobemide and being a MAO-AB inhibitor it has the antidepressant, anti-Parkinson and anti-Alzheimer activities in the respective models used to develop such drugs.

Source; MedScape

PubMed Articles [13632 Associated PubMed Articles listed on BioPortfolio]

Activation studies of the α- and β-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with amines and amino acids.

The α- and β-class carbonic anhydrases (CAs, EC 4.2.1.1) from the pathogenic bacterium Vibrio cholerae, VchCAα, and VchCAβ, were investigated for their activation with natural and non-natural amin...

Antileishmanial activity of sulphonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species.

The β-carbonic anhydrase (CA, EC 4.2.1.1) from Leishmania spp. (LdcCA) is effectively inhibited by aromatic/heterocyclic sulphonamides, in the low nanomolar range, but no in vitro antileishmanial act...

Advances in the discovery of cathepsin K inhibitors on bone resorption.

Cathepsin K (Cat K), highly expressed in osteoclasts, is a cysteine protease member of the cathepsin lysosomal protease family and has been of increasing interest as a target of medicinal chemistry ef...

Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation.

Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour, and phytotoxic act...

Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma.

Chemical entities with structural diversity were introduced as candidates targeting adenosine receptor with different clinical activities, containing 3,7-dihydro-1H-purine-2,6-dione, especially adenos...

Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.

Human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2), being an age-old target, has attracted attention recently for anticancer drug development. Mycophenolic acid (MPA), a well-known immunosuppres...

N-terminal-pro-B-type-natriuretic peptide associated with 2-year mortality from both cardiovascular and non-cardiovascular origins in prevalent chronic hemodialysis patients.

N-terminal-pro-B-type-natriuretic peptide (NT-proBNP) was a predictive marker of cardiovascular disease (CVD)-related death in chronic dialysis patients. NT-proBNP was also correlated with markers of ...

Ultrasound assisted fabrication of a novel optode base on a triazine based Schiff base immobilized on TEOS for copper detection.

This work introduces novel selective and sensitive optical sensor based on a nano sized triazine based Schiff base (HL) immbolized on a transparent glass substrate through the sol-gel process to detec...

Blurriness-Guided Unsharp Masking.

In this paper, a highly-adaptive unsharp masking (UM) method is proposed and called the blurriness-guided UM, or BUM, in short. The proposed BUM exploits the estimated local blurriness as the guidance...

Characterizations of the endogenous starch hydrolase inhibitors in acorns of Quercus fabri Hance.

The acorns of Quercus fabri Hance tree, or the mandarin duck fruits have been consumed by locals in the form of noodle, yet there is little scientific study. We found that they have much lower digesti...

News Articles [8267 Associated News Articles listed on BioPortfolio]

Eli Lilly: Lispro Shows Improved Blood Sugar Control In Phase 1b Studies

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced its ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes...

Medtronic gets US FDA nod for use of MiniMed 670G system patients with type 1 diabetes seven years of age and older

Medtronic plc, the global leader in medical technology, announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes seven ...

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

Data Presented at the 78th Scientific Sessions of the American Diabetes Association THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repa...

Handling Rheum Side Effects of New Cancer Drugs

(MedPage Today) -- Study examines emerging problem with immune checkpoint inhibitors

Pack the Right Footwear for Summer Vacations

SATURDAY, June 23, 2018 -- When packing for your summer vacation, be sure to include the right footwear, a podiatrist advises. "The type of vacation you go on will determine the type of shoe you need,...

[Comment] Agonism of receptors in the gut–pancreas axis in type 2 diabetes: are two better than one?

Pharmacotherapy for type 2 diabetes has become complex with the advent of a large number of treatment options. Major goals of therapy include achieving glycaemic targets (glycated haemoglobin [HbA1c] ...

[Articles] MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

MEDI0382 has the potential to deliver clinically meaningful reductions in blood glucose and bodyweight in obese or overweight individuals with type 2 diabetes.

Sealants generally show equal performance regardless of tooth type and position

Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafg...

Risk of autism increased in children of mothers with diabetes

(JAMA Network) The risk of autism spectrum disorder (ASD) was increased in children of mothers with the three main types of diabetes that complicate pregnancy, findings that add new information on typ...

Events [0 Results]

None

Companies [257 Associated Companies listed on BioPortfolio]

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...

VALBIOTIS

VALBIOTIS is a French Research & Development company committed to scientific innovation, for preventing and fighting against metabolic diseases. Its products are made for manufact...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The compa...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology an...

Galecto Biotech AB

Galectin-3 is a member of the galectin family of galactoside binding lectins. Galectin-3 exists both intra- and extracellularly and binds to glycosylated proteins. Galectin-3 has ...

Bormioli Pharma

Bormioli Pharma exclusively serves the pharmaceutical and biopharmaceutical market with integrated glass and plastic containers, closures and accessories for packaging, using stat...

Zucara Therapeutics

Zucara Therapeutics, a spin-off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycem...

Tetra Discovery Partners Inc.

Tetra Discovery Partners is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Alzhe...

Targeted Oncology™

TargetedOnc.com provides the latest news and insight on next-generation therapeutics and their molecular targets for practicing oncologists. As the field of oncology continues to ...

BioCell Technology

BioCell Collagen is a clinically tested dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen contains a patented...

Clinical Trials [5652 Associated Clinical Trials listed on BioPortfolio]

Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors

To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of ...

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol

Primary objective: To assess the effects of a modified plant-based Mediterranean diet (vegeterranean diet), circuit resistance training (CRT) and empagliflozin alone or in combination on b...

A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes

This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2 diabetes. A...

Severe and Transient Hypoxemia During Selective Intra-arterial Chemotherapy for Retinoblastoma in Children: Evaluation of the Right-sided Heart Function.

Children having selective ophthalmic artery chemotherapy for retinoblastoma under general anaesthesia may experience troubles during the procedure. The troubles are transient, may be sever...

Selective Use of Episiotomy: the Impact on Perineal Trauma.

Vaginal delivery is commonly accompanied by trauma of the genital tract. Perineal trauma is classified into four degrees based on anatomic structures involved and severity of lacerations a...

Triglyceride Rich Lipoproteins and Platelet Activation in Type 2 Diabetes

To investigate in vitro the effect of triglyceride rich lipoproteins (TGRL) obtained in type 2 diabetic women in the fasting state and following a randomized isocaloric lipid rich breakfas...

Tai Chi Quan Improving Biochemistry and Quality of Life in Type 2 Diabetes

In this study, the hypothesis that the 12-week Tai Chi Quan training would have better control of blood sugar, biochemistry profile, and also better quality of life and activity of autonom...

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitati...

Olaparib in Recurrent IDH-mutant Glioma

Recent data demonstrate that in IDH-mutant gliomas, 2 hydroxy-glutarate production induces a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosin...

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitati...

Videos

None available.

Medical and Biotech [MESH] Definitions

A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.

An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4.

One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.

An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.

A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stress
Stress is caused by your perception of situations around you and then the reaction of your body to them. The automatic stress response to unexpected events is known as 'fight or flight'. Discovered by Walter Cannon in 1932, it is the release of h...

review and buy Selective monoamine oxidase type B MAOB inhibitors market research data and corporate reports here

Channels Quicklinks